OnKure Therapeutics, Inc. (NASDAQ:OKUR) Short Interest Update

OnKure Therapeutics, Inc. (NASDAQ:OKUR) was the target of a large growth in short interest during the month of June. As of June 30th, there was short interest totaling 878,668 shares, a growth of 211.1% from the June 15th total of 282,400 shares. Approximately 2.2% of the company’s shares are short sold. Based on an average daily volume of 755,793 shares, the short-interest ratio is presently 1.2 days.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Wall Street Zen raised shares of OnKure Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. JonesTrading downgraded shares of OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 7th. Weiss Ratings upgraded shares of OnKure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 29th. Finally, HC Wainwright cut their price objective on OnKure Therapeutics from $34.00 to $27.00 and set a “buy” rating on the stock in a research report on Monday, March 16th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, OnKure Therapeutics has an average rating of “Hold” and an average target price of $27.00.

OnKure Therapeutics Trading Up 2.7%

OKUR traded up $0.11 during trading on Tuesday, reaching $4.22. The stock had a trading volume of 87,738 shares, compared to its average volume of 279,813. The stock’s 50 day moving average is $4.13 and its two-hundred day moving average is $3.69. The company has a market capitalization of $170.49 million, a price-to-earnings ratio of -0.97 and a beta of 0.27. OnKure Therapeutics has a one year low of $1.91 and a one year high of $5.38.

OnKure Therapeutics (NASDAQ:OKUR) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.37). On average, equities research analysts predict that OnKure Therapeutics will post -3.19 earnings per share for the current year.

Institutional Investors Weigh In On OnKure Therapeutics

Several hedge funds have recently bought and sold shares of the business. XTX Topco Ltd bought a new position in shares of OnKure Therapeutics during the second quarter valued at approximately $25,000. Rangeley Capital LLC bought a new stake in shares of OnKure Therapeutics in the 2nd quarter worth approximately $71,000. Shay Capital LLC grew its stake in shares of OnKure Therapeutics by 417.8% in the 2nd quarter. Shay Capital LLC now owns 782,046 shares of the company’s stock worth $1,869,000 after buying an additional 631,008 shares during the last quarter. Rosalind Advisors Inc. purchased a new stake in shares of OnKure Therapeutics in the 4th quarter worth approximately $2,118,000. Finally, Renaissance Technologies LLC increased its position in OnKure Therapeutics by 40.7% during the 4th quarter. Renaissance Technologies LLC now owns 247,350 shares of the company’s stock valued at $717,000 after buying an additional 71,600 shares in the last quarter. Institutional investors own 90.98% of the company’s stock.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.